In addition to the well-known drivers of lung cancer, EGFR (55.7%), KRAS (5.2%), BRAF (2.0%), HER2 (0.7%) mutations, and EML4-ALK translocation (9.8%) [128], a body of epidemiological evidence, preclinical in vitro and in vivo studies, and recent data from the clinical trials, support estrogen as an important factor that contributes to lung carcinogenesis, lung cancer growth, metastasis, and affecting the prognosis. The gene discussed is ALK; the disease is lung cancer.